Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli
详细信息 查看全文
- 作者：Stina Sö ; derlund ; MDa ; b ; c ; stina.soderlund@igp.uu.se" class="auth_mail" title="E-mail the corresponding author ; stina.soderlund@akademiska.se" class="auth_mail" title="E-mail the corresponding author ; Lisa Christianssona ; Inger Perssond ; Henrik Hjorth-Hansene ; f ; Johan Richterg ; Bengt Simonssonb ; Satu Mustjokih ; i ; Ulla Olsson-Strö ; mbergb ; c ; Angelica Loskoga
- 关键词：Proteomics ; Chronic myeloid leukemia ; Tyrosine kinase inhibitor ; Th1 ; Angiogenesis
- 刊名：Leukemia Research
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：50
- 期：Complete
- 页码：95-103
- 全文大小：1418 K
文摘
- •
Plasma proteomics seems feasible and useful in CML patients.
- •
Protein patterns demonstrated a shift towards Th1-immunity after TKI treatment.
- •
Angiogenic factors were decreased after TKI treatment.
- •
Some single analytes were identified that could be of interest to study further in CML.